Akebia Therapeutics (AKBA)
Akebia Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
23.1M
Short interest
settlement 2026-10-15
3.0
Days to cover
-0.5 days vs prior
57.2%
Short share of volume
2026-11-02
1,314
Fails to deliver
settlement 2026-10-14
Mon 9 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in AKBA is 23,071,255 shares, up 2,566,340 shares over the last month. Over the last 48 readings it ranged from 11,557,619 shares (29 November 2024) to 37,025,281 shares (15 January 2026). At the reported average volume of 7.8M shares a day that is 3.0 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/akba" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 23,071,255 | +2.6% | 7,794,014 | 2.96 |
| 2026-09-30 | 22,481,147 | +9.6% | 6,412,381 | 3.51 |
| 2026-09-15 | 20,504,915 | -10.9% | 7,439,437 | 2.76 |
| 2026-08-31 | 23,002,561 | +7.6% | 9,826,387 | 2.34 |
| 2026-08-14 | 21,371,566 | +11.4% | 6,044,103 | 3.54 |
| 2026-07-31 | 19,183,020 | +0.6% | 2,177,153 | 8.81 |
| 2026-07-15 | 19,076,806 | -0.5% | 4,543,375 | 4.20 |
| 2026-06-30 | 19,177,371 | -34.3% | 7,120,957 | 2.69 |
| 2026-06-15 | 29,201,925 | +6.5% | 5,214,571 | 5.60 |
| 2026-05-29 | 27,420,606 | +4.0% | 6,624,978 | 4.14 |
| 2026-05-15 | 26,371,163 | -4.5% | 4,638,423 | 5.69 |
| 2026-04-30 | 27,621,774 | +1.1% | 2,433,231 | 11.35 |
| 2026-04-15 | 27,313,287 | +4.0% | 2,026,908 | 13.48 |
| 2026-03-31 | 26,266,098 | -9.4% | 2,811,344 | 9.34 |
| 2026-03-13 | 28,988,090 | -2.4% | 2,804,123 | 10.34 |
| 2026-02-27 | 29,692,868 | -4.8% | 3,254,556 | 9.12 |
| 2026-02-13 | 31,207,330 | -15.5% | 4,396,546 | 7.10 |
| 2026-01-30 | 36,927,875 | -0.3% | 2,609,774 | 14.15 |
| 2026-01-15 | 37,025,281 | +2.7% | 3,337,924 | 11.09 |
| 2025-12-31 | 36,058,633 | +4.3% | 2,835,925 | 12.71 |
| 2025-12-15 | 34,581,801 | -3.7% | 3,351,672 | 10.32 |
| 2025-11-28 | 35,918,701 | +1.6% | 3,529,859 | 10.18 |
| 2025-11-14 | 35,344,201 | -0.5% | 6,462,599 | 5.47 |
| 2025-10-31 | 35,517,452 | +21.1% | 5,510,936 | 6.44 |
| 2025-10-15 | 29,319,644 | -0.3% | 2,687,857 | 10.91 |
| 2025-09-30 | 29,401,452 | +7.5% | 3,190,649 | 9.21 |
| 2025-09-15 | 27,363,386 | +1.0% | 3,859,359 | 7.09 |
| 2025-08-29 | 27,090,731 | +9.2% | 3,833,176 | 7.07 |
| 2025-08-15 | 24,814,352 | +1.1% | 4,502,272 | 5.51 |
| 2025-07-31 | 24,538,006 | -3.3% | 3,063,807 | 8.01 |
| 2025-07-15 | 25,373,233 | -0.5% | 3,453,699 | 7.35 |
| 2025-06-30 | 25,504,822 | +37.9% | 4,908,029 | 5.20 |
| 2025-06-13 | 18,498,837 | -7.8% | 7,824,186 | 2.36 |
| 2025-05-30 | 20,053,575 | +1.7% | 5,137,665 | 3.90 |
| 2025-05-15 | 19,722,763 | +11.0% | 4,497,731 | 4.39 |
| 2025-04-30 | 17,770,222 | -0.8% | 2,888,147 | 6.15 |
| 2025-04-15 | 17,922,367 | +3.3% | 5,010,261 | 3.58 |
| 2025-03-31 | 17,357,699 | +4.8% | 7,127,696 | 2.44 |
| 2025-03-14 | 16,570,902 | +11.4% | 4,228,947 | 3.92 |
| 2025-02-28 | 14,879,018 | -0.7% | 2,396,279 | 6.21 |
| 2025-02-14 | 14,981,253 | +3.6% | 1,612,570 | 9.29 |
| 2025-01-31 | 14,453,171 | -19.7% | 2,698,999 | 5.36 |
| 2025-01-15 | 17,994,029 | +7.9% | 2,155,107 | 8.35 |
| 2024-12-31 | 16,678,310 | +18.5% | 2,085,518 | 8.00 |
| 2024-12-13 | 14,069,487 | +21.7% | 2,099,412 | 6.70 |
| 2024-11-29 | 11,557,619 | -3.4% | 1,909,781 | 6.05 |
| 2024-11-15 | 11,961,601 | -19.4% | 2,841,464 | 4.21 |
| 2024-10-31 | 14,835,319 | -16.1% | 2,148,384 | 6.91 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of AKBA volume is 57.2%, up 2.8 points over the last five sessions. Over the last 30 readings it ranged from 50.4% (22 September 2026) to 78.4% (6 October 2026). The latest reading is 7.0 points below the 30-session average of 64.2%, on 3.4M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 2.0M | 3.4M | 57.2% | 1,000 |
| 2026-10-30 | 1.0M | 1.8M | 56.3% | 5,349 |
| 2026-10-29 | 2.3M | 3.4M | 66.0% | 51,246 |
| 2026-10-28 | 3.0M | 4.5M | 67.1% | 5,675 |
| 2026-10-27 | 2.3M | 3.5M | 65.3% | 3,341 |
| 2026-10-26 | 4.7M | 8.6M | 54.5% | 15,040 |
| 2026-10-23 | 5.8M | 9.3M | 62.6% | 50,280 |
| 2026-10-22 | 7.3M | 10.9M | 67.1% | 25,800 |
| 2026-10-21 | 11.8M | 16.1M | 73.6% | 348,744 |
| 2026-10-20 | 4.7M | 8.0M | 58.7% | 125,819 |
| 2026-10-19 | 3.4M | 6.2M | 54.6% | 100 |
| 2026-10-16 | 2.6M | 4.7M | 54.5% | 121,664 |
| 2026-10-15 | 3.9M | 7.5M | 52.1% | 0 |
| 2026-10-14 | 6.1M | 11.7M | 52.5% | 33,053 |
| 2026-10-13 | 3.2M | 5.0M | 64.4% | 16,699 |
| 2026-10-12 | 4.9M | 7.4M | 66.0% | 2,126 |
| 2026-10-09 | 3.2M | 4.5M | 70.9% | 43,490 |
| 2026-10-08 | 3.1M | 4.3M | 73.7% | 22,679 |
| 2026-10-07 | 5.6M | 7.8M | 71.9% | 8,700 |
| 2026-10-06 | 4.2M | 5.3M | 78.4% | 0 |
| 2026-10-05 | 4.1M | 6.2M | 66.7% | 0 |
| 2026-10-02 | 4.0M | 5.5M | 74.1% | 3,182 |
| 2026-10-01 | 2.3M | 3.4M | 69.3% | 2,500 |
| 2026-09-30 | 5.4M | 8.9M | 60.8% | 32,939 |
| 2026-09-29 | 1.6M | 2.6M | 63.5% | 46,500 |
| 2026-09-28 | 1.8M | 2.6M | 71.8% | 0 |
| 2026-09-25 | 2.3M | 3.1M | 73.9% | 28,179 |
| 2026-09-24 | 1.7M | 2.6M | 65.2% | 2,800 |
| 2026-09-23 | 2.7M | 4.4M | 62.8% | 6,000 |
| 2026-09-22 | 2.0M | 3.9M | 50.4% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in AKBA is 1,314 shares, unchanged over the last settlement date. Over the last 30 readings it ranged from 1,314 shares (2 September 2026) to 151,739 shares (18 September 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 1,314 | $0.77 | $1K |
| 2026-10-13 | 1,314 | $0.79 | $1K |
| 2026-10-09 | 94,802 | $0.81 | $77K |
| 2026-10-08 | 14,675 | $0.87 | $13K |
| 2026-10-07 | 1,314 | $0.88 | $1K |
| 2026-10-06 | 1,314 | $0.91 | $1K |
| 2026-10-05 | 1,314 | $0.87 | $1K |
| 2026-10-02 | 1,314 | $0.87 | $1K |
| 2026-10-01 | 24,695 | $0.92 | $23K |
| 2026-09-30 | 1,314 | $0.89 | $1K |
| 2026-09-29 | 1,314 | $0.89 | $1K |
| 2026-09-28 | 1,314 | $0.90 | $1K |
| 2026-09-25 | 1,314 | $0.92 | $1K |
| 2026-09-24 | 1,314 | $0.93 | $1K |
| 2026-09-23 | 1,949 | $0.98 | $2K |
| 2026-09-22 | 1,314 | $0.94 | $1K |
| 2026-09-21 | 1,314 | $0.92 | $1K |
| 2026-09-18 | 151,739 | $0.90 | $137K |
| 2026-09-17 | 1,314 | $0.92 | $1K |
| 2026-09-16 | 1,314 | $0.90 | $1K |
| 2026-09-15 | 1,314 | $0.96 | $1K |
| 2026-09-14 | 1,314 | $0.95 | $1K |
| 2026-09-11 | 12,183 | $0.95 | $12K |
| 2026-09-10 | 3,707 | $0.95 | $4K |
| 2026-09-09 | 1,314 | $1.03 | $1K |
| 2026-09-08 | 1,314 | $0.97 | $1K |
| 2026-09-04 | 1,314 | $0.98 | $1K |
| 2026-09-03 | 1,314 | $0.98 | $1K |
| 2026-09-02 | 1,314 | $0.94 | $1K |
| 2026-09-01 | 2,009 | $0.92 | $2K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for AKBA in the last 90 days. The most recent filings are listed below. Latest filing: Butler John P. (CEO and President) on 2026-08-06.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-06 | Butler John P. | CEO and President | Exercise or conversion | 350K | $0.63 | $221K | 3.7M |
| 2026-06-29 | Ostrowski Erik | SVP, CFO, CBO & Treasurer | Sell | 56K | $1.11 | $62K | 617K |
| 2026-06-17 | FRIESON RON | Director | Grant | 36K | $0.00 | $0 | 165K |
| 2026-06-17 | Wolf Myles | Director | Grant | 36K | $0.00 | $0 | 169K |
| 2026-06-17 | Smith Cynthia | Director | Grant | 36K | $0.00 | $0 | 197K |
| 2026-06-17 | ROGERS MICHAEL W | Director | Grant | 36K | $0.00 | $0 | 197K |
| 2026-06-17 | ZUMWALT LEANNE M | Director | Grant | 36K | $0.00 | $0 | 145K |
| 2026-06-17 | ADAMS ADRIAN | Director | Grant | 36K | $0.00 | $0 | 236K |
| 2026-03-04 | Butler John P. | CEO and President | Buy | 69K | $1.25 | $87K | 3.4M |
| 2026-02-02 | Rucci Carolyn M. | SVP, Chief Legal Officer | Sell | 28K | $1.39 | $38K | 588K |
| 2026-02-02 | Rucci Carolyn M. | SVP, Chief Legal Officer | Sell | 25K | $1.39 | $35K | 616K |
| 2026-02-02 | Rucci Carolyn M. | SVP, Chief Legal Officer | Sell | 17K | $1.39 | $23K | 641K |
| 2026-02-02 | Malabre Richard C | SVP, Chief Accounting Officer | Sell | 13K | $1.39 | $19K | 299K |
| 2026-02-02 | Malabre Richard C | SVP, Chief Accounting Officer | Sell | 36K | $1.39 | $50K | 313K |
| 2026-02-02 | Ostrowski Erik | SVP, CFO, CBO & Treasurer | Sell | 35K | $1.39 | $49K | 673K |
| 2026-02-02 | Grund Nicholas | Chief Commercial Officer | Sell | 31K | $1.39 | $43K | 562K |
| 2026-02-02 | Grund Nicholas | Chief Commercial Officer | Sell | 54K | $1.39 | $74K | 593K |
| 2026-02-02 | Burke Steven Keith | SVP, Chief Medical Officer | Sell | 21K | $1.39 | $29K | 948K |
| 2026-02-02 | Burke Steven Keith | SVP, Chief Medical Officer | Sell | 25K | $1.39 | $35K | 969K |
| 2026-02-02 | Burke Steven Keith | SVP, Chief Medical Officer | Sell | 22K | $1.39 | $30K | 995K |
| 2026-02-02 | Butler John P. | CEO and President | Sell | 84K | $1.39 | $116K | 3.3M |
| 2026-02-02 | Butler John P. | CEO and President | Grant | 175K | $1.41 | $247K | 3.4M |
| 2026-02-02 | Butler John P. | CEO and President | Sell | 115K | $1.39 | $160K | 3.2M |
| 2026-02-02 | Butler John P. | CEO and President | Sell | 96K | $1.39 | $134K | 3.3M |
| 2026-02-02 | Butler John P. | CEO and President | Sell | 47K | $1.39 | $65K | 3.4M |
| 2026-01-30 | Rucci Carolyn M. | SVP, Chief Legal Officer | Grant | 190K | $0.00 | $0 | 658K |
| 2026-01-30 | Malabre Richard C | SVP, Chief Accounting Officer | Grant | 79K | $0.00 | $0 | 349K |
| 2026-01-30 | Ostrowski Erik | SVP, CFO, CBO & Treasurer | Grant | 204K | $0.00 | $0 | 708K |
| 2026-01-30 | Grund Nicholas | Chief Commercial Officer | Grant | 204K | $0.00 | $0 | 647K |
| 2026-01-30 | Burke Steven Keith | SVP, Chief Medical Officer | Grant | 204K | $0.00 | $0 | 1.0M |
| 2026-01-30 | Butler John P. | CEO and President | Grant | 743K | $0.00 | $0 | 3.5M |
| 2025-06-30 | Ostrowski Erik | SVP, CFO, CBO & Treasurer | Sell | 41K | $3.67 | $152K | 504K |
| 2025-06-10 | FRIESON RON | Director | Grant | 36K | $0.00 | $0 | 130K |
| 2025-06-10 | GILMAN STEVEN C | Director | Grant | 36K | $0.00 | $0 | 153K |
| 2025-06-10 | ROGERS MICHAEL W | Director | Grant | 36K | $0.00 | $0 | 162K |
| 2025-06-10 | Smith Cynthia | Director | Grant | 36K | $0.00 | $0 | 161K |
| 2025-06-10 | Wolf Myles | Director | Grant | 36K | $0.00 | $0 | 133K |
| 2025-06-10 | ADAMS ADRIAN | Director | Grant | 36K | $0.00 | $0 | 201K |
| 2025-06-10 | ZUMWALT LEANNE M | Director | Grant | 36K | $0.00 | $0 | 109K |
| 2025-06-09 | Malabre Richard C | SVP, Chief Accounting Officer | Exercise or conversion | 15K | $1.68 | $25K | 282K |
| 2025-06-09 | Malabre Richard C | SVP, Chief Accounting Officer | Sell | 15K | $4.01 | $60K | 267K |
| 2025-06-04 | Malabre Richard C | SVP, Chief Accounting Officer | Sell | 13K | $3.53 | $47K | 267K |
| 2025-03-03 | Burke Steven Keith | SVP, Chief Medical Officer | Sell | 7K | $1.83 | $13K | 809K |
| 2025-03-03 | Butler John P. | CEO and President | Sell | 46K | $1.83 | $85K | 2.6M |
| 2025-02-03 | Grund Nicholas | Chief Commercial Officer | Sell | 56K | $2.10 | $117K | 443K |
| 2025-02-03 | Malabre Richard C | SVP, Chief Accounting Officer | Sell | 30K | $2.10 | $63K | 280K |
| 2025-02-03 | Burke Steven Keith | SVP, Chief Medical Officer | Sell | 27K | $2.10 | $57K | 816K |
| 2025-02-03 | Burke Steven Keith | SVP, Chief Medical Officer | Sell | 23K | $2.10 | $49K | 843K |
| 2025-02-03 | Butler John P. | CEO and President | Sell | 98K | $2.10 | $206K | 2.6M |
| 2025-02-03 | Butler John P. | CEO and President | Sell | 46K | $2.10 | $97K | 2.7M |
| 2025-01-31 | Ostrowski Erik | SVP, CFO, CBO & Treasurer | Grant | 195K | $0.00 | $0 | 545K |
| 2025-01-31 | Grund Nicholas | Chief Commercial Officer | Grant | 195K | $0.00 | $0 | 498K |
| 2025-01-31 | Malabre Richard C | SVP, Chief Accounting Officer | Grant | 85K | $0.00 | $0 | 310K |
| 2025-01-31 | Burke Steven Keith | SVP, Chief Medical Officer | Grant | 195K | $0.00 | $0 | 867K |
| 2025-01-31 | Butler John P. | CEO and President | Grant | 701K | $0.00 | $0 | 2.7M |
| 2025-01-17 | FRIESON RON | Director | Exercise or conversion | 20K | $0.45 | $9K | 94K |
| 2024-06-28 | Ostrowski Erik | SVP, CFO, CBO & Treasurer | Grant | 350K | $0.00 | $0 | 350K |
| 2024-06-06 | ADAMS ADRIAN | Director | Grant | 30K | $0.00 | $0 | 165K |
| 2024-06-06 | ZUMWALT LEANNE M | Director | Grant | 30K | $0.00 | $0 | 74K |
| 2024-06-06 | FRIESON RON | Director | Grant | 30K | $0.00 | $0 | 74K |
| 2024-06-06 | GILMAN STEVEN C | Director | Grant | 30K | $0.00 | $0 | 117K |
| 2024-06-06 | ROGERS MICHAEL W | Director | Grant | 30K | $0.00 | $0 | 126K |
| 2024-06-06 | Smith Cynthia | Director | Grant | 30K | $0.00 | $0 | 125K |
| 2024-06-06 | Wolf Myles | Director | Grant | 30K | $0.00 | $0 | 98K |
| 2024-05-13 | Dahan Michel | SVP, Chief Operating Officer | Sell | 35K | $1.26 | $44K | 672K |
| 2024-05-13 | Hadas Nicole R. | SVP, Chief Legal Officer | Sell | 12K | $1.26 | $15K | 651K |
| 2024-02-29 | Burke Steven Keith | SVP, Chief Medical Officer | Sell | 7K | $1.58 | $11K | 696K |
| 2024-02-29 | Butler John P. | CEO and President | Sell | 47K | $1.58 | $74K | 2.0M |
| 2024-02-29 | Hadas Nicole R. | SVP, Chief Legal Officer | Sell | 6K | $1.58 | $9K | 663K |
| 2024-02-29 | Dahan Michel | SVP, Chief Operating Officer | Sell | 9K | $1.58 | $14K | 707K |
| 2024-02-27 | Butler John P. | CEO and President | Sell | 38K | $1.52 | $57K | 2.1M |
| 2024-02-27 | Burke Steven Keith | SVP, Chief Medical Officer | Sell | 8K | $1.52 | $13K | 703K |
| 2024-02-27 | Dahan Michel | SVP, Chief Operating Officer | Sell | 11K | $1.52 | $16K | 716K |
| 2024-02-27 | Hadas Nicole R. | SVP, Chief Legal Officer | Sell | 7K | $1.52 | $11K | 669K |
| 2024-02-01 | Burke Steven Keith | SVP, Chief Medical Officer | Sell | 24K | $1.68 | $41K | 711K |
| 2024-02-01 | Butler John P. | CEO and President | Sell | 46K | $1.68 | $78K | 2.1M |
| 2024-01-31 | Burke Steven Keith | SVP, Chief Medical Officer | Grant | 202K | $0.00 | $0 | 736K |
| 2024-01-31 | Butler John P. | CEO and President | Grant | 604K | $0.00 | $0 | 2.2M |
| 2024-01-31 | Hadas Nicole R. | SVP, Chief Legal Officer | Grant | 149K | $0.00 | $0 | 677K |
| 2024-01-31 | Snow Ellen | SVP, CFO and Treasurer | Grant | 149K | $0.00 | $0 | 519K |
| 2024-01-31 | Dahan Michel | SVP, Chief Operating Officer | Grant | 149K | $0.00 | $0 | 726K |
| 2024-01-31 | Malabre Richard C | Chief Accounting Officer | Grant | 224K | $0.00 | $0 | 224K |
| 2024-01-31 | Grund Nicholas | Chief Commercial Officer | Grant | 303K | $0.00 | $0 | 303K |
| 2023-08-25 | Burke Steven Keith | SVP, Chief Medical Officer | Sell | 27K | $1.15 | $31K | 669K |
| 2023-07-31 | Snow Ellen | SVP, CFO and Treasurer | Grant | 370K | $0.00 | $0 | 370K |
| 2023-06-06 | GILMAN STEVEN C | Director | Grant | 30K | $0.00 | $0 | 87K |
| 2023-06-06 | Smith Cynthia | Director | Grant | 30K | $0.00 | $0 | 95K |
| 2023-06-06 | ADAMS ADRIAN | Director | Grant | 30K | $0.00 | $0 | 135K |
| 2023-06-06 | Wolf Myles | Director | Grant | 30K | $0.00 | $0 | 68K |
| 2023-06-06 | FRIESON RON | Director | Grant | 30K | $0.00 | $0 | 44K |
| 2023-06-06 | ROGERS MICHAEL W | Director | Grant | 30K | $0.00 | $0 | 96K |
| 2023-06-06 | ZUMWALT LEANNE M | Director | Grant | 30K | $0.00 | $0 | 44K |
| 2023-05-25 | Dahan Michel | SVP, Chief Operating Officer | Sell | 95K | $1.22 | $116K | 574K |
| 2023-05-25 | Hadas Nicole R. | SVP, Chief Legal Officer | Sell | 63K | $1.22 | $77K | 524K |
| 2023-05-24 | Dahan Michel | SVP, Chief Operating Officer | Grant | 200K | $0.00 | $0 | 670K |
| 2023-05-24 | Hadas Nicole R. | SVP, Chief Legal Officer | Grant | 200K | $0.00 | $0 | 588K |
| 2023-05-16 | Spellman David A | SVP, CFO and Treasurer | Sell | 64K | $1.07 | $68K | 446K |
| 2023-05-16 | Burke Steven Keith | SVP, Chief Medical Officer | Sell | 64K | $1.07 | $68K | 530K |
| 2023-05-12 | Dahan Michel | SVP, Chief Operating Officer | Grant | 200K | $0.00 | $0 | 470K |
| 2023-05-12 | Hadas Nicole R. | SVP, Chief Legal Officer | Grant | 100K | $0.00 | $0 | 388K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON6 Form 144 notices on file for AKBA worth $897K at the prices reported; 0 in the last 90 days worth $0. Latest: Ostrowski Erik filed on 2026-06-29 to sell 56,019 shares ($62K) from 2026-06-29.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-06-29 | Ostrowski ErikOfficer | 56K | $62K | 0.021% | 2026-06-29 | Morgan Stanley Smith Barney LLC |
| 2026-02-02 | Ostrowski ErikOfficer | 35K | $49K | 0.013% | 2026-02-02 | Morgan Stanley Smith Barney LLC |
| 2026-02-02 | Grund NicholasOfficer | 85K | $118K | 0.032% | 2026-02-02 | Morgan Stanley Smith Barney LLC |
| 2026-02-02 | Burke Steven KeithOfficer | 68K | $94K | 0.025% | 2026-02-02 | Morgan Stanley Smith Barney LLC |
| 2026-02-02 | Butler John P.Officer | 341K | $476K | 0.129% | 2026-02-02 | Morgan Stanley Smith Barney LLC |
| 2026-02-02 | Rucci Carolyn M.Officer | 70K | $97K | 0.026% | 2026-02-02 | Morgan Stanley Smith Barney LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON1 holder reports 5% or more of AKBA in its latest filing, on Schedule 13G (passive). The holder is BlackRock, Inc. at 7.2% of the class (19,219,819 shares), filed 2026-01-21 for an event on 2025-12-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-05-12 | 13G | STATE STREET CORPORATIONparent holding company | 11.6M | 4.3% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 1 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-01-21 | 13G/Ano. 2 | BlackRock, Inc.parent holding company | 19.2M | 7.2% | 2025-12-31 |
13F holders
Tracked managers holding AKBA at their latest 13F. JSON6 of the 30 tracked managers held AKBA at their latest 13F, $20.3M in total at quarter-end prices. AQR Capital Management is the largest at $10.4M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| AQR Capital Management | 2026-06-30 | 9.2M | $10.4M | 0.00% | +7.4M |
| Millennium Management | 2026-06-30 | 3.2M | $3.6M | 0.00% | +812K |
| Two Sigma Investments | 2026-06-30 | 2.4M | $2.8M | 0.00% | +1.1M |
| Citadel Advisors | 2026-06-30 | 1.7M | $2.0M | 0.00% | +328K |
| Renaissance Technologies | 2026-06-30 | 1.2M | $1.4M | 0.00% | -609K |
| D. E. Shaw & Co. | 2026-06-30 | 88K | $100K | 0.00% | +72K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Akebia Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Akebia Therapeutics (AKBA), SEC CIK 1517022, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-06-29.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-05-12.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-05.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-08-06.JSON and CSV
- Company record
- EDGAR filing index for CIK 1517022Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of AKBA is sold short?
23,071,255 shares were held short at the 2026-10-15 settlement, 3.0 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is AKBA's daily short volume?
On 2026-11-02, 1,961,947 of the 3,429,574 AKBA shares reported to FINRA were sold short, 57.2% of the day's reported volume. Short volume is a flow for one day, not a position.
Does AKBA have fails to deliver?
The SEC's latest file shows 1,314 AKBA shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.
Are AKBA insiders buying or selling?
No open-market insider trades were reported for AKBA in the last 90 days. The most recent filings are listed below. Latest filing: Butler John P. (CEO and President) on 2026-08-06.
Have AKBA insiders filed to sell?
6 Form 144 notices on file for AKBA worth $897K at the prices reported; 0 in the last 90 days worth $0. Latest: Ostrowski Erik filed on 2026-06-29 to sell 56,019 shares ($62K) from 2026-06-29.
Who owns 5% or more of AKBA?
1 holder reports 5% or more of AKBA in its latest filing, on Schedule 13G (passive). The holder is BlackRock, Inc. at 7.2% of the class (19,219,819 shares), filed 2026-01-21 for an event on 2025-12-31.
Which tracked 13F managers own AKBA?
6 of the 30 tracked 13F managers held AKBA shares at their latest filing, $20.3M in all. The largest: Cliff Asness's AQR Capital Management (9.2M shares, $10.4M), Izzy Englander's Millennium Management (3.2M shares, $3.6M), Two Sigma Investments (2.4M shares, $2.8M), Ken Griffin's Citadel Advisors (1.7M shares, $2.0M), Renaissance Technologies (1.2M shares, $1.4M), D. E. Shaw & Co. (88K shares, $100K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.